Comparison · NCT01149369-e793cc11
Aprepitant vs Aprepitant-placebo: Number of Participants With Improvement in Nausea
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Aprepitant vs Aprepitant-placebo: Number of Participants With Improvement in Nausea. Trial comparisons, record NCT01149369-e793cc11. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01149369-e793cc11
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.46 | 0.343 | 0.582 | wilson | |
| Risk in group 2 | 0.397 | 0.285 | 0.52 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0635 | -0.107 | 0.229 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.16 | 0.774 | 1.74 | log | |
| Odds ratio, group 1 over group 2 | 1.3 | 0.639 | 2.63 | log | |
| Number needed to treat, for one more participant with the outcome on Aprepitant than on Aprepitant-placebo | 15.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Aprepitant | Aprepitant 125 mg per day~Aprepitant: Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks | 29 | 63 | OG000 |
| Group 2 | Aprepitant-placebo | Placebo aprepitant 125mg per day~Placebo: Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks | 25 | 63 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Improvement in Nausea
- Description
The primary outcome measure is a binary (0,1) variable indicating improvement in nausea or not in the mean of available visual analog scale (VAS) scores over the 28 day treatment period compared to the mean of VAS scores during the 7 day baseline period. The criteria for improvement are either a 25 mm or more reduction in mean VAS or attaining a mean VAS during the treatment period of \< 25 mm.
- Time frame
- 4 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
- NCT number
- NCT01149369
- Phases
- PHASE2
- Conditions
- Gastroparesis
- Interventions
- Aprepitant, Placebo
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Results first posted
- 2019-05-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01149369?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01149369-e793cc11